Gamma Oryzanol

Gamma Oryzanol

SCHEMBL21235210

COc1cc(/C=C/C(=O)O[C@H]2CC[C@]34C[C@]35CC[C@]3(C)[C@@H](C(C)CCC=C(C)C)CC[C@@]3(C)[C@@H]5CC[C@H]4C2(C)C)ccc1O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ ACLY P53396 2/20 0.50
▸ ACACA Q13085 2/20 0.50
▸ RELA Q04206 1/20 0.49
▸ MAPT P10636 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ GAA P10253 2/20 0.48
▸ XBP1 P17861 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ SLC10A1 Q14973 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ PTPN1 P18031 1/20 0.41
▸ PTGS1 P23219 1/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ PTPN11 Q06124 1/20 0.39
▸ ELANE P08246 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gamma Oryzanol SCHEMBL23105398 1.00 MEN1 (0.60) MEN1KMT2AACLYACACARELA
Gamma Oryzanol SCHEMBL29357024 1.00 MEN1 (0.60) MEN1KMT2AACLYACACARELA
Gamma Oryzanol SCHEMBL12152368 1.00 MEN1 (0.60) MEN1KMT2AACLYACACARELA
Gamma Oryzanol SCHEMBL29354302 1.00 MEN1 (0.60) MEN1KMT2AACLYACACARELA
Gamma Oryzanol SCHEMBL718726 1.00 MEN1 (0.60) MEN1KMT2AACLYACACARELA
SCHEMBL10049046 0.94 MEN1 (0.53) MEN1KMT2AACLYACACARELA
SCHEMBL31149054 0.94 ACLY (0.52) MEN1KMT2AACLYACACARELA
SCHEMBL10017450 0.90 MEN1 (0.51) MEN1KMT2AACLYACACARELA
SCHEMBL12152371 0.90 MEN1 (0.63) MEN1KMT2AACLYACACARELA
SCHEMBL29524845 0.90 MEN1 (0.63) MEN1KMT2AACLYACACARELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10568892-B2 Cycloartane tetracyclic triterpenoid compound, preparation method therefor and use thereof HEFEI COSOURCE PHARMACEUTICALS INC. (CN) 2020-02-25 — — US disclosed
US-20190240238-A1 CYCLOARTANE TETRACYCLIC TRITERPENOID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF HEFEI BLOOMING DRUG SAFETY EVALUATION CO., LTD. (CN) 2019-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190240238-A1 CYCLOARTANE TETRACYCLIC TRITERPENOID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF CYP51A1, CYP4A11, CYP46A1 MEN1 587/4885KMT2A 4010/4885ACLY 3439/4885
US-10568892-B2 Cycloartane tetracyclic triterpenoid compound, preparation method therefor and use thereof CYP51A1, CYP4A11, CYP46A1 MEN1 587/4885KMT2A 4010/4885ACLY 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback